Drug Trial Radar · NCT06104917
Effect of Maolactin on Gastrointestinal Tract (GIT) Health
Last checked: Nov 19, 2026Latest source record: Aug 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
91
Actual
Start
Feb 21, 2024
Primary completion
Jul 23, 2025
Study completion Jul 23, 2025
Sponsor
- Lead sponsor
- RDC Clinical Pty LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Maolac
- First posted
- Oct 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, 3 arm parallel group study of 12 weeks duration, with a 4-week run-in period as the control phase and an 8-week intervention period, to investigate the effectiveness of the treatment on upper GI disturbance.
Conditions
- Gastrointestinal Dysfunction
Interventions
High Dose MaolactinDrug
Once daily dose of 2 capsules (2 capsules containing 250mg active proteins per capsule; equivalent to 500mg active proteins per day)
Low Dose MaolactinDrug
Once daily dose of 2 capsules (1 capsule containing 250mg active proteins per capsule and 1 capsule containing maltodextrin only; equivalent to 250mg active proteins per day)
MaltodextrinDrug
Once daily dose of 2 capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in upper gastrointestinal symptomsTime frame: Day -28, Day 0, Day 14, Day 28, Day 56
Locations
1 site in 1 country. Site status is shown where the registry gives one.
RDC Clinical Pty Ltd
Brisbane, Queensland, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.